Topics:

Enrollment Begins for Phase I Trial of NPI-0052 in Myeloma

Enrollment Begins for Phase I Trial of NPI-0052 in Myeloma

NORWALK, Connecticut—The Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., San Diego, have initiated enrollment in a multicenter phase I clinical trial to study Nereus' novel, second-generation proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. Participants in the open-label study will receive escalating, once-weekly intravenous doses of NPI-0052. The compound was discovered during the fermentation of a new marine actinomycete (Salinispora tropica).

 
Loading comments...
Please Wait 20 seconds or click here to close